Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 6686 record(s)

Req # A-2023-001476

Adverse Drug Reactions (ADRs). Report numbers: 001067920, 001068172, 001069831.

Organization: Health Canada

73 page(s)
February 2025

Req # A-2024-000384

Adverse Drug Reaction (ADR) for Vedolizumab. Report number: 001083331. ADRs for Ondansetron. Report numbers: 001085629, E2B_07094075, 001086064. ADRs for Pantoloc. Report numbers: 001082313, E2B_07093184, 001085766. ADR for Pantoprazole sodium.…

Organization: Health Canada

2664 page(s)
February 2025

Req # A-2024-000389

Adverse Drug Reactions (ADRs) for Antihemophilic factor (human). Report numbers: E2B_07072699. (ADR) for Prevacid. Report number: E2B_07102854. ADRs for Lansoprazole. Report numbers: E2B_07073455, E2B_07081362, E2B_07090888, E2B_07066410,…

Organization: Health Canada

2947 page(s)
February 2025

Req # A-2024-000438

Adverse Drug Reaction (ADR). Report number: E2B_03819673.

Organization: Health Canada

298 page(s)
February 2025

Req # A-2024-000518

Adverse Drug Reaction (ADR). Report number: E2B_07159863.

Organization: Health Canada

8 page(s)
February 2025

Req # A-2024-000608

Adverse Drug Reactions (ADRs) for Pantoprazole sodium. Report numbers: 001094200, E2B_07224935, 001093143, 001101763, E2B_07240542, E2B_07238941, E2B_07223245. ADRs for Tecta. Report numbers: E2B_07196650, E2B_07210775, E2B_07199512.

Organization: Health Canada

1008 page(s)
February 2025

Req # A-2024-000610

Adverse Drug Reactions (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_07240241, E2B_07202397, E2B_07203738, E2B_07211715, E2B_07200893, E2B_07212141, 001091444. ADR for Mesalimine. Report number: 001097077. ADR for VYVANSE. Report…

Organization: Health Canada

234 page(s)
February 2025

Req # A-2024-000613

Adverse Drug Reactions (ADRs) for GAMMAGARD LIQUID. Report numbers: 001092359, 001092364, 001090767, 001091341, 001090112, 001090121, 001090932, 001090109, 001090130. ADR for Prevacid. Report number: E2B_07222484.

Organization: Health Canada

128 page(s)
February 2025

Req # A-2024-000633

Adverse Drug Reactions (ADRs). Report numbers: 001090397, 001090829, 001095271, 001090911, E2B_07193408.

Organization: Health Canada

52 page(s)
February 2025

Req # A-2024-000702

Adverse Drug Reactions (ADRs). Report numbers: E2B_04932036, E2B_06747039.

Organization: Health Canada

34 page(s)
February 2025
Date modified: